MRKMerck Sharp & Dohme LLCSigning up patients
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 1,530 (planned)
- Started
- Jun 24, 2024
- Main results expected
- Dec 16, 2030
- Fully finished
- Dec 14, 2037
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Invasive Disease-Free Survival (iDFS)
Measured over: Up to ~77 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06393374 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC